Drug intelligence / Profile preview

CT-004

Development stage: Preclinical
Lead developer: Coagulant Therapeutics

Overview

CT-004 is an investigational therapeutic candidate being developed by Coagulant Therapeutics, currently in the IND-enabling phase of development. Coagulant Therapeutics focuses on the design of therapies for acute bleeding and coagulation-related conditions, utilizing platforms such as engineered coagulation factors and nanobodies. As of early 2024, specific information regarding the molecular target, modality, and primary indication for CT-004 has not been publicly disclosed by the developer, although it is positioned within a pipeline targeting severe hemorrhage and hematological disorders.

Beyond the preview

Go deeper on CT-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-004.

Explore the full profile